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A recently described genetic disorder has been associated with 13q12.3 microdeletion spanning three genes, namely, KATNAL1,
LINC00426, and HMGB1. Here, we report a new case with similar clinical features that we have followed from birth to 5 years
old. The child carried a complex rearrangement with a double translocation: 46,XX,t(7;13)(p15;q14),t(11;15)(q23;q22). Array-CGH
identified a de novo microdeletion at 13q12.2q13.1 spanning 3–3.4Mb and overlapping 13q12.3 critical region. Clinical features
resembling those reported in the literature confirm the existence of a distinct 13q12.3 microdeletion syndrome and provide further
evidence that is useful to characterize its phenotypic expression during the 5 years of development.
1. Introduction
Array-CGH has gained increased recognition as a first-tier
technique to identify and characterize the genetic determi-
nants of intellectual disability (ID) syndromes. Following
its introduction, the detection rate of molecular cytogenetic
alterations has increased by up to 15% in unselected patients
with ID [1, 2]. The possibility of comparing patient pheno-
types with overlapping rearrangements has led to the identifi-
cation of several novel microdeletion/microduplication syn-
dromes [2]. A 13q12.3 microdeletion syndrome has recently
been described involving a ∼300 kb critical region spanning
only three genes, namely, KATNAL1, HMGB1, and the non-
coding RNA LINC00426 [3].
Here, we describe a Caucasian patient with a de novo
complex chromosomal rearrangement [t(7;13) and t(11;15)]
including a 3–3.4Mb microdeletion on 13q12.2q13.1, overlap-
ping with the 13q12.3 microdeletion syndrome region. This
subject displays the characteristic dysmorphic features high-
lighted in the recently reported cases, as well as psychomotor
developmental delay and markedly delayed speech.
2. Clinical Report
The proband was the third daughter of a 41-year-old mother
and a 42-year-old father. Both parents and siblings were
healthy. Prenatal ultrasounds did not reveal any foetal
malformations. Prenatal karyotype analysis by standard
GTG banding, performed due to advanced maternal age,
showed a de novo double translocation [46,XX,t(7;13)
(p15;q14),t(11;15)(q23;q22)] (Figure 1(a)); UPD was ruled out
for chromosomes 7, 11, and 15. Birth occurred through elective
caesarean section at the 38th week of gestation (APGAR
7/8). Birth parameters were at the 50th centile according to
the Italian growth curves (length: 50 cm (50th cent); weight:
2.79 kg (50th cent); head circumference: 34.5 cm (50th cent)).
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Figure 1: Karyotype, array-CGH analysis and schematic representation of the deleted region with reported DECIPHER cases. (a) The G-
band karyotype of the patient. Black arrows indicate translocated chromosomes. (b) Chromosome 13 array-CGH results [arr 13q12.2q13.1
(28,875,081x2, 28,963,865-31,955,272x1, 32,313,799x2)dn]. (c) A scheme of the deleted region with distances in Mb and the Refseq genes are
reported (GRCh37/hg19). The region deleted in our patient (code: 263218, orange bar) and the overlapping reported deletions (red bars) as
shown by the Decipher database (http://decipher.sanger.ac.uk/, version 5.1) are reported. Above each bar the extension of the rearrangement
and the mode of inheritance is reported (dn: de novo; pat: paternal origin, and un: unknown).
We excluded cerebral malformations by brain ultrasound
analysis and ocular defects by carrying out a fundus oculi
exam. ECG examination showed a long QT (QTc: 470ms),
which was not reconfirmed at 17 days. Dysmorphisms
included large wide set eyes, long philtrum, thin upper lip,
and large ears (Figure 2). An angioma was present on the
thorax and another was found on the top of the head.
From infancy to the last follow-up at 5 years old, growth
parameters were consistently below target levels. At 5 years,
the measured parameters of the child were as follows: height:
100 cm (3rd cent); weight: 13 kg (<3rd cent/−2.8 SD); head
circumference: 49 cm (10th cent). She displayed psychomotor
delay: at 8 months she was unable to sit unsupported and at
18 months, after physiotherapy treatment, she still required
support for walking. Lallation began at 16 months and
language development was markedly impaired (at 5 years
she pronounced very few words that included phonological
alterations). The Griffiths test performed at 20 months old
revealed a mental age of 14.4 months.
Examination at 2 years old revealed a normal EEG but
brain MRI showed mild hypomyelination of the subcortical
regions and thinning of the corpus callosum. Urinary and
plasmatic aminoacid screenings were normal.
Postnatal array-CGH 44K (Agilent, Santa Clara, CA)
performed at 1 year old identified a 3–3.4Mb microdele-
tion on chromosome 13q12.2q13.1, close to the translocation
breakpoint on chromosome 13 (Figure 1(b)). The deletion
was shown to span from position 28,963,865 to 31,955,272
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Figure 2: Proposita at 12 weeks, 8 months, 3 years, and 5 years old.
(minimal region) (NCBI Build 37/hg19), to contain 20 tran-
scripts (15 coding genes), and did not overlap with com-
mon copy number variants (Database of Genomic Variants,
http://projects.tcag.ca/variation/) (Figure 1(c)). The deletion
was confirmed by real-time quantitative PCR assay designed
to target exon 4 of the microtubule-associated tumour sup-
pressor candidate 2 gene (MTUS2, NM 001033602.2). The
same assay was used to confirm the de novo origin of this
rearrangement.
3. Discussion
The 13q12.3 microdeletion syndrome was recently described
in three patients presentingwith intellectual disability,micro-
cephaly, and eczema/atopic dermatitis [3]. Here, we describe
a fourth patient with strikingly similar dysmorphic features,
confirming the presence of a recognizable phenotype.
Common clinical features included reduced head circum-
ference, triangular face, high frontal hairline, large ears, wide
set eyes, fullness of eyelids, malar flattening, a prominent
nose with underdeveloped alae nasi and low insertion col-
umella, thin upper lip vermilion, and a pointed chin. Our
patient had one episode of cutaneous rash, but a specific
diagnosis of atopic dermatitis was not made. All patients
have shown delayed speech development andmoderate intel-
lectual deficit. In three out of four patients recurrent upper
airway respiratory infections were reported. Other features
shared by the described patients (namely, recurrent vomiting,
failure to thrive, allergies, abnormal vision, oligodontia, or
truncal obesity) were not observed in our proband.
Several other deletions and duplications that partially or
totally overlap the present one, which are associated with a
particular phenotype, are reported in the Decipher database
(https://decipher.sanger.ac.uk/) (Figure 1(c) and Table 1). In
particular, four deletions are partially or totally included
in the deletion of this case study (DECIPHER cases num-
bers 249924, 282282, 4587, 266456, and 279188) and these
patients show intellectual disability, language delay, micro-
cephaly, and facial dysmorphisms. Moreover, behavioural
abnormalities similar to the ones described by Bartholdi
et al. were reported in two cases (Table 1). The minimal
shared region between these deletions and the deletion
reported in our patient includes the three genes KATNAL1
(MIM 614764), LOC100188949, and HMGB1 (MIM 163905)
[3]. A causal role can be easily suggested for HMGB1
only, which encodes a ubiquitous nonhistone chromoso-
mal protein expressed in brain (Allen Mouse Brain Atlas,
http://mouse.brain-map.org/). This is a possible dosage-
sensitive gene involved in the inflammatory response that
may contribute to neuronal excitability and seizures [4, 5].
Three other geneswithin the deleted region in our patient,
but not found to be involved in the patients investigated
by Bartholdi et al., are associated with OMIM phenotypes:
(i) UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase-like
(B3GALTL, MIM 610308), which is mutated in the autosomal
recessive Peters plus syndrome (MIM 261540), characterized
by anterior eye-chamber abnormalities, disproportionate
short stature, and developmental delay [6]; (ii) arachidonate
5-lipoxygenase-activating protein (ALOX5AP, MIM 603700)
gene, whose sequence variants confer increased susceptibility
to stroke (MIM 603700) [7]; (iii) proteasome maturation
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protein (POMP, MIM 613386) gene, which is associated with
the recessive phenotype keratosis linearis with ichthyosis
congenita and sclerosing keratoderma (MIM601952) [8].The
clinical features of these diseases are not clearly related to our
patient’s phenotype, in line with the recessive nature of the
associated syndromes. Comparison of our patient with the
four reported in Decipher did not suggest any phenotypic
effect of the additional deleted genes in the 13q12.2q13.1
region. Moreover, we cannot exclude the occurrence of posi-
tion effect or gene disruption at any of the breakpoints of this
complex karyotype and the deletion span may contribute to
the phenotypic differences. Thus, the gene(s) responsible for
the phenotypic differences with reference to the individuals
in the study of Bartholdi et al. presently remains elusive.
The relevance of the 13q12q13 deletion, currently sup-
ported by the phenotypic similarity and de novo deletion
origin of the three DECIPHER cases, the three individuals
reported by Bartholdi et al., and our affected subject will be
confirmed by identifying additional cases, in particular those
carrying point mutations in HMGB1 or another gene in this
region.
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